Silence Therapeutics plc

NASDAQ:SLN

Biotechnology

Healthcare
$19.80 +2.81%

+$0.19 today

Market cap
$935.23M
Beta
1.48
P/E (TTM)
-3.9
EPS (TTM)
-$1.80
52W Low $4.19High $8.40

Volume 1.21M

Average 0.31M

SLN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Silence Therapeutics plcNASDAQ: SLN

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$14.83M, compared with -$36.73M a year earlier. Trailing-twelve-month EBITDA was -$78.13M.

Context

  • EBITDA amounted to 15750.6% of revenue in FY2025, up 15637.4 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$3.84M (+95.6%) for the fiscal year ending Dec 2026, a step up from the -79.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.83M-27.2% QoQ
Last fiscal yearDec 2025
-$88.05M-79.7% YoY
LTMMar 2026
-$78.13M— YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.6%+95.5%+35.8 pp
1 year-79.7%+95.6%+175.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

Mixed currencies · from the income statement

Latest · FY2025
(88.05M) USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How SLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • EBITDA amounts to 8478.5% of revenue for SLN, versus a peer median of 148.9%.
SLN Competitors
EBITDA for SLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$124.95M USD+217.3%—5.7%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€42.88M EUR-67.7%—319.0%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$53.46M USD-44.4%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$67.53M USD-3.7%—148.9%
RNAAtrium Therapeutics, Inc.FY2025-$76.5M USD——410.9%
SLNSilence Therapeutics plcLTM Mar 2026-$78.13M USD——8478.5%
WVEWave Life Sciences Ltd.LTM Mar 2026-$174.59M USD-68.4%—243.2%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$473.54M USD-208.3%—49.3%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$603.58M USD-466.2%—133.9%
ADRXADARx Pharmaceuticals, Inc.—— ———
Peer median (excluding SLN) —-67.7%—148.9%

Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · GBP
FY2025
Dec 2025 · USD
Revenue12.42M17.65M25.38M43.26M559K
Cost of Revenue7.46M10.97M10.32M11.81M215K
Gross Profit4.96M6.68M15.06M31.45M344K
Gross Margin39.9%37.8%59.3%72.7%61.5%
Research & Development30.77M35.5M44.03M67.88M67.75M
Selling, General & Admin20.01M20.94M20.64M26.88M22.34M
Operating Expenses50.77M56.44M64.66M94.77M90.1M
Depreciation & Amortization427K485.86K498K593K555K
EBITDA(45.42M)(39.94M)(49.78M)(48.99M)(88.05M)
EBITDA Margin-365.9%-226.2%-196.2%-113.2%-15750.6%
Operating Income(45.81M)(49.76M)(49.6M)(63.32M)(89.75M)
Operating Margin-369.0%-281.9%-195.5%-146.4%-16056.0%
Interest Income10K226K1.45M4.47M3.48M
Interest Expense8K47K34K00
Other Income / Expenses(42K)9.29M(706K)18.86M1.15M
Income Before Tax(45.86M)(40.47M)(50.31M)(44.46M)(88.6M)
Pre-Tax Margin-369.4%-229.3%-198.3%-102.8%-15849.9%
Income Tax Expense(6.45M)560.85K(7.04M)845K11K
Net Income(39.41M)(41.03M)(43.27M)(45.31M)(88.61M)
Net Margin-317.4%-232.4%-170.5%-104.7%-15851.9%
EPS (Basic)(1.35)(3.78)(3.48)(2.37)(1.89)
EPS (Diluted)(1.35)(3.78)(3.48)(2.37)(1.89)
Weighted Avg Shares29.65M10.73M12.36M15.42M47.23M
Weighted Avg Shares (Diluted)29.65M10.73M12.36M15.42M47.23M

Silence Therapeutics plc

NASDAQ:SLN

Intrinsic Alpha fair value

Locked

Current Price

$19.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.